The estimated Net Worth of Jeffrey A Munsie is at least $909 millier dollars as of 15 February 2023. Mr. Munsie owns over 3,762 units of Concert Pharmaceuticals Inc stock worth over $736,970 and over the last 7 years he sold CNCE stock worth over $171,696. In addition, he makes $0 as Chief Legal Officer et Secretary at Concert Pharmaceuticals Inc.
Sign up
Mr. Munsie CNCE stock SEC Form 4 insiders trading
Jeffrey has made over 6 trades of the Concert Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,762 units of CNCE stock worth $31,375 on 15 February 2023.
The largest trade he's ever made was selling 8,493 units of Concert Pharmaceuticals Inc stock on 30 January 2023 worth over $70,917. On average, Jeffrey trades about 1,598 units every 46 days since 2017. As of 15 February 2023 he still owns at least 88,049 units of Concert Pharmaceuticals Inc stock.
You can see the complete history of Mr. Munsie stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeffrey Munsie biography
Jeffrey A. Munsie serves as Chief Legal Officer, Secretary of the Company. Mr. Munsie has served as our Chief Legal Officer and Secretary since September 2019. Prior to joining Concert, Mr. Munsie served as General Counsel, Head of Corporate Operations and Secretary at Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, until July 2019. Mr. Munsie joined Merrimack in February 2011 and became Secretary in August 2011, General Counsel in January 2013 and Head of Corporate Operations in March 2017. Previously, Mr. Munsie was Counsel in the corporate department at Wilmer Cutler Pickering Hale and Dorr LLP, a law firm, where he practiced from 2002 to January 2011. Mr. Munsie received an A.B from Dartmouth College and a J.D. from Harvard Law School.
How old is Jeffrey Munsie?
Jeffrey Munsie is 42, he's been the Chief Legal Officer et Secretary of Concert Pharmaceuticals Inc since 2019. There are 15 older and no younger executives at Concert Pharmaceuticals Inc. The oldest executive at Concert Pharmaceuticals Inc is Peter Hutt, 85, who is the Independent Director.
What's Jeffrey Munsie's mailing address?
Jeffrey's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.
Insiders trading at Concert Pharmaceuticals Inc
Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... et Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.
What does Concert Pharmaceuticals Inc do?
Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.
What does Concert Pharmaceuticals Inc's logo look like?
Complete history of Mr. Munsie stock trades at Concert Pharmaceuticals Inc et Merrimack Pharmaceuticals Inc
Concert Pharmaceuticals Inc executives and stock owners
Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Roger Tung,
President, Chief Executive Officer, Co-Founder, Director -
Nancy Stuart,
Chief Operating Officer -
Marc Becker,
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer -
James Cassella,
Chief Development Officer -
Dr. Roger D. Tung,
Co-Founder, CEO, Pres & Exec. Director -
Dr. James V. Cassella,
Chief Devel. Officer -
Jesper Hoiland,
Independent Director -
Richard Aldrich,
Independent Chairman of the Board, Co-Founder -
Thomas Auchincloss,
Independent Director -
Ronald Barrett,
Independent Director -
Peter Hutt,
Independent Director -
Christine van Heek,
Independent Director -
Wilfred Jaeger,
Independent Director -
Richard H. Aldrich M.B.A., Mba,
Co-Founder & Chairman -
Justine Koenigsberg,
Senior Vice President, Corporate Communications and Investor Relations -
Jeffrey Munsie,
Chief Legal Officer, Secretary -
Christine Boisclair,
Sr. VP of Regulatory Affairs & Quality Assurance -
Dr. Nabil Uddin Pharm.D.,
VP of Corp. Devel. -
Jeffrey A. Munsie,
Chief Legal Officer & Corp. Sec. -
Marc A. Becker,
CFO & Principal Accounting Officer -
Nancy Stuart,
Chief Operating Officer -
Wendall Wierenga,
Director -
Wilfred Ethree Arch Managem...,
-
Pauline Mc Gowan,
VP, Finance -
D. Ryan Daws,
Chief Financial Officer -
Robert Silverman,
Senior VP, General Counsel -
Meghan Fitzgerald,
Director -
Lynette Herscha,
General Counsel -
Heek Christi Van,
Director -
Ryan Lynch,
PAO -
Partners L P/Ilbiotechnolog...,
-
Leaf Ventures I, L.P.New Le...,
-
Helmut Schuhsler,
Director -
John Gordon Freund,
Director -
Associates Gp Llcqvt Fund V...,
-
Capital Management Llcbrook...,
-
Ventures Fund 2004 L P Flag...,
-
Plc Gsk,
-
Capital Partners, L.P.Adage...,
-
Venture Partners Qualified ...,
-
Life Science Ventures Vi Gm...,
-
Arch Management Iv, L.L.C.J...,
-
Arch Management Iii Llcthre...,
-
Arch Management Iv, L.L.C.J...,
-
Xii Gp Llc Greylock Xii Lim...,
-
Arch Management Iii Llcjaeg...,
-
Jesper Hoeiland,
Director -
Marc A. Becker,
Chief Financial Officer